Program
Please Note: All session times for the AACR Virtual Meeting: Myeloma – Discovery to Therapy are U.S. Eastern Standard Time (EST).
Monday, April 26, 2021
- Session 1: Disease Progression from Precursor Conditions to Myeloma
- Session 2: Genomics and Epigenetics of Myeloma
Tuesday, April 27, 2021
- Session 3: Myeloma Microenvironment and Immunotherapy
- Session 4: Novel Therapeutics and Drug Resistance
- Panel Discussion: Bench to Bedside – Clinical Trials and Drug Development in Myeloma
MONDAY, APRIL 26, 2021
Session 1: Disease Progression from Precursor Conditions to Myeloma
Moderators: Irene Ghobrial, Dana-Farber Cancer Institute, Boston, MAssachusetts, and Ola Landgren, University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida
10-11:20 a.m.
The genomic basis of smoldering multiple myeloma progression
Salomon Manier, University of Lille, Lille, France
Imaging based predictors of disease progression in early stages of monoclonal plasma cell disorders
Jens Hillengass, Roswell Park Comprehensive Cancer Center, Buffalo, New York
How to manage smoldering myeloma?
María-Victoria Mateos, University of Salamanca, Salamanca, Spain
Panel Discussion
Break
11:20-11:35 a.m.
Session 2: Genomics and Epigenetics of Myeloma
Moderator: Brian Walker, Indiana University–Purdue University Indianapolis, Indianapolis, Indiana
11:35 a.m.-12:55 p.m.
Understanding multiple myeloma life history using whole-genome sequencing
Francesco Maura, University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida
Title to be announced
Constantine Mitsiades, Dana-Farber Cancer Institute, Boston, Massachusetts
The definition of high-risk disease
Faith E. Davies, NYU Langone Health, New York, New York
Panel Discussion
TuesDAY, APRIL 27, 2021
Session 3: Myeloma Microenvironment and Immunotherapy
Moderators: Gad Getz, Broad Institute of MIT and Harvard, Cambridge, MASSACHUSETTS, and Nikhil C. Munshi, Dana-Farber Cancer Institute, Boston, Massachusetts
10-11:20 a.m.
Title to be announced
Madhav V. Dhodapkar, Emory University, Atlanta, Georgia
Advances in adoptive cellular therapy for multiple myeloma
Eric L. Smith, Dana-Farber Cancer Institute, Boston, Massachusetts
Panel Discussion
Break
11:20-11:35 a.m.
Session 4: Novel Therapeutics and Drug Resistance
Moderators: Paola Neri, University of Calgary, Calgary, Alberta, Canada, and Paula Rodríguez-Otero, University of Navarra, Pamplona, Spain
11:35 a.m.-12:55 p.m.
Targeting the BCL2 family in multiple myeloma
Lawrence H. Boise, Emory Winship Cancer Institute, Atlanta, Georgia
Targeted therapies in relapsed/refractory multiple myeloma
Marc S. Raab, Heidelberg University Hospital, Heidelberg, Germany
Treatment of lenalidomide refractory patients
Francesca Gay, University of Torino, Torino, Italy
Panel Discussion
Break
12:55-1:10 p.m.
Panel Discussion: Bench to Bedside – Application of Lessons Learned from COVID-19 to Clinical Trials and Drug Development in Myeloma
Moderator: Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Massachusetts
1:10-2 p.m.
Kenneth C. Anderson
Daniel Auclair, Multiple Myeloma Research Foundation, Norwalk, Connecticut
Nicole J. Gormley, FDA Center for Drug Evaluation & Research, Silver Spring, Maryland
Craig L. Tendler, Johnson & Johnson Pharmaceutical R&D, New Brunswick, New Jersey